Kornblith P L, Rosa L, Bona J D, Edwards J A, Matuzic N, Hirschfeld A, Hawkins C
J Neurooncol. 1986;4(1):49-54. doi: 10.1007/BF02158002.
In a series of 28 glioma-derived cell cultures and 6 non-gliomatous CNS tumors, AZQ has been found to have varying degrees of growth inhibiting or cytotoxic activity in nearly all lines tested at doses greater than 100 mcg/ml. At dose levels comparable to the clinically achieved levels (1 mcg/ml), AZQ was found to have a cytotoxic effect in 8 of 28 glioma-derived and 2 of 6 non-gliomatous cell lines tested. These findings suggest that AZQ has activity against certain glioma-derived cells in culture at a response ratio similar to that seen in vivo. There, appear to be significant differences in the degree of responsiveness in different patients' tumor cells which can be detected in vitro prior to clinical treatment.
在一系列28种胶质瘤衍生细胞培养物和6种非胶质瘤性中枢神经系统肿瘤中，已发现当剂量大于100微克/毫升时，AZQ在几乎所有测试细胞系中都具有不同程度的生长抑制或细胞毒性活性。在与临床达到的水平（1微克/毫升）相当的剂量水平下，在测试的28种胶质瘤衍生细胞系中有8种、6种非胶质瘤细胞系中有2种发现AZQ具有细胞毒性作用。这些发现表明，AZQ在培养中对某些胶质瘤衍生细胞具有活性，其反应率与体内观察到的相似。在临床治疗前可在体外检测到，不同患者肿瘤细胞的反应程度似乎存在显著差异。
